Initial results from an ongoing phase 2 trial examining the combination of PD-0332991 and letrozole in ER+/HER2– breast cancer patients showed significant improvements in progression-free survival, as well as higher response and clinical benefit rates with the combination compared with letrozole alone[31]. Here, ESR1 is linked to breast carcinoma.